| Ytd | 75.90% | |
| 1y | 199.98% |
| Open | 132.75 | Prev Close | 132.73 | Low | 132.69 | High | 132.85 | Mkt Cap | 9.98B |
| Vol | 3.48M | Avg Vol | 2.40M | EPS | -4.33 | P/E | N/A | Forward P/E | -25.59 |
| Beta | 0.62 | Short Ratio | 9.81 | Inst. Own | 131.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 91.77 | 200-d Avg | 73.18 | 1yr Est | 130.53 |
APGE News
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for po
AbbVie knows how to plan ahead.
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, ap
Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 2
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 bill
Stifel analyst Akash Tewari downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold and rai
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi
Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See
Mizuho analyst Joseph Catanzaro downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform to N
Deutsche Bank analyst David Hoang downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold a
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology
Top Wall Street analysts changed outlook on top names. Piper Sandler upgraded SNPS, JP Morgan upgrad
Citigroup analyst Geoff Meacham downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral
RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perf
Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo
UBS analyst Michael Yee downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral and rais
Wall Street analysts changed ratings for PRIM, ZION, and APGE. Check out analysts' views on thes
Wedbush analyst David Nierengarten downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform t
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar
Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for
SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth
https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?syn-25a6b1a6=1
RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perf